Adjuvant therapy for laryngeal papillomatosis

Department of Otorhinolaryngology and Cervicofacial Surgery, Ljubljana University Medical Center, Slovenia.
Acta dermatovenerologica Alpina, Panonica, et Adriatica 09/2011; 20(3):175-80.
Source: PubMed


Respiratory papillomatosis affects the larynx in most cases. It is a relatively rare disease, with potentially devastating consequences for the patient. Many studies have proven the viral etiology of the disease. Surgery is the most successful mode of treatment. Adjuvant therapy is used in cases of aggressive disease. The most successful adjuvant drugs are interferon, various virostatics (e.g., acyclovir, valacyclovir, and cidofovir) and indole-3-carbinol. Vaccination with a quadrivalent vaccine against HPV will probably decrease the incidence of respiratory papillomatosis or help in the treatment of the disease in the future. The results of adjuvant therapy of laryngeal papillomatosis at the University Department of ORL & HNS in Ljubljana are comparable to the results in other centers around the world.

1 Follower
48 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Laryngeal papillomatosis is a rare benign tumour of larynx generally observed in children. Material and methods From January 2004 to December 2010, 21 patients with laryngeal papillomatosis have been recorded. Results The mean age at the time of diagnosis was 6 years and the sex ratio was 1.11. All children were dysphonic, and 52% had laryngeal dyspnea. The tracheotomy was done in 76%. The only available treatment in our department was stripping by forceps due to direct laryngoscopy under general anaesthesia. Histological study was done systematically. Decannulation was performed in 100% of patients. Conclusion The management of laryngeal papillomatosis raises major therapeutic difficulties. There is not an etiological treatment right now. Capricious evolution of this pathology requires regular monitoring of patients.
    Journal de Pédiatrie et de Puériculture 10/2012; 25(5):237–241. DOI:10.1016/j.jpp.2012.06.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Surgical management of recurrent respiratory papillomatosis (RRP) usually involves resection via microlaryngoscopy. Intralesional injection of cidofovir has been shown to be an effective adjuvant treatment, but remains unlicensed. United Kingdom General Medical Council guidelines recommend the prescribing doctor should "be satisfied that there is a sufficient evidence base and/or experience of using the medicine to demonstrate its safety and efficacy". This study reviews the published dosing regimens of intralesional cidofovir in the treatment of RRP in order to provide a precedent for those that wish to prescribe it. Methods: A systematic review of the literature was undertaken using Medline, EMBASE and CINAHL. Articles describing the use of intralesional cidofovir for RRP were reviewed. Information regarding cidofovir concentration, volume, total dose, number of treatments, interval between treatments, overall treatment period and follow up was extracted. Results: Fifty-one articles were identified. Concentration of cidofovir injected ranged from 0.0001mg/ml to 37.5mg/ml, with 5 to 7.5mg/ml being the most common. The volume of cidofovir solution injection ranged from 0.1 to 20ml. The total dose per injection ranged from 0.15 to 105mg. There was wide variation in dosing regimens with different intervals between endoscopies, number of injections and total doses delivered. Conclusions: Based on this published literature, the precedent for prescribing intralesional cidofovir supports a concentration of 5 to 7.5mg/ml. Volumes up to 5ml per injection are routinely used. Total dose and frequency of cidofovir administration is highly variable. The need for repeat doses of cidofovir should be judged on an individual basis.
    International journal of pediatric otorhinolaryngology 01/2013; 77(3). DOI:10.1016/j.ijporl.2012.12.027 · 1.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is an HPV-related neoplasm affecting primarily the larynx. JORRP often requires repeated surgical debridement, which yield variable but generally moderate remission periods. We report the case of a 6-year-old boy with severe course JORRP since the age of 2, requiring tracheostomy, that underwent prolonged remission and was decannulated some months after administration of the HPV vaccine. The post-exposure use for the anti-HPV vaccine in JORRP is a topic of capital interest but still poorly characterized. Some published cases suggest a potential post-exposure role of the vaccine in JORRP, but prospective multicentric trials are still needed.
    International journal of pediatric otorhinolaryngology 12/2013; 78(2). DOI:10.1016/j.ijporl.2013.12.013 · 1.19 Impact Factor
Show more

Similar Publications


48 Reads
Available from
May 22, 2014